TriSalus Life Sciences Statistics
Want to see TLSI full AI Analyst Report?
TriSalus Life Sciences (TLSI) Stock Statistics & Valuation Metrics
Total Valuation
TriSalus Life Sciences has a market cap or net worth of $175.49M. The enterprise value is $244.65M.
- Market Cap
- $175.49M
- Enterprise Value
- $244.65M
Share Statistics
TriSalus Life Sciences has 61,574,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 61,574,600
- Owned by Insiders
- 28.15%
- Owned by Institutions
- 15.41%
Financial Efficiency
TriSalus Life Sciences’s return on equity (ROE) is 1.16 and return on invested capital (ROIC) is -112.28%.
- Return on Equity (ROE)
- 1.16
- Return on Assets (ROA)
- -1.11
- Return on Invested Capital (ROIC)
- -112.28%
- Return on Capital Employed (ROCE)
- -1.13
- Revenue Per Employee
- 442.66K
- Profits Per Employee
- -384.58K
- Employee Count
- 102
- Asset Turnover
- 1.28
- Inventory Turnover
- 2.26
Valuation Ratios
The current PE Ratio of TriSalus Life Sciences is -4.69. TriSalus Life Sciences’s PEG ratio is -0.03.
- PE Ratio
- -4.69
- PS Ratio
- 3.05
- PB Ratio
- 197.78
- Price to FCF
- -4.52
- Price to Operating Cash Flow
- -4.36
- PEG Ratio
- -0.03
Income Statement
In the last 12 months, TriSalus Life Sciences had revenue of 45.15M and earned -39.23M in profits. Earnings per share was -1.84.
- Revenue
- 45.15M
- Gross Profit
- 38.19M
- Operating Income
- -26.95M
- Pretax Income
- -39.22M
- Net Income
- -39.23M
- EBITDA
- -33.05M
- Earnings Per Share (EPS)
- -1.84
Cash Flow
In the last 12 months, operating cash flow was -30.85M and capital expenditures -495,000, giving a free cash flow of -31.34M billion.
- Operating Cash Flow
- -30.85M
- Free Cash Flow
- -31.34M
- Free Cash Flow per Share
- -0.54
Dividends & Yields
TriSalus Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -22.13%
- Earnings Yield
- -19.52%
Stock Price Statistics
- Beta
- 1.21
- 52-Week Price Change
- -47.00%
- 50-Day Moving Average
- 4.29
- 200-Day Moving Average
- 4.34
- Relative Strength Index (RSI)
- 22.49
- Average Volume (3m)
- 282.22K
Important Dates
TriSalus Life Sciences upcoming earnings date is Apr 05, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 10, 2026
- Next Earnings Date
- Apr 05, 2027
- Ex-Dividend Date
- ―
Financial Position
TriSalus Life Sciences as a current ratio of 2.80, with Debt / Equity ratio of -101.71%
- Current Ratio
- 2.80
- Quick Ratio
- 2.54
- Debt to Market Cap
- 0.13
- Net Debt to EBITDA
- -0.42
- Interest Coverage Ratio
- -4.86
Taxes
In the past 12 months, TriSalus Life Sciences has paid 7,000 in taxes.
- Income Tax
- 7,000
- Effective Tax Rate
- -0.00
Enterprise Valuation
TriSalus Life Sciences EV to EBITDA ratio is -6.79, with an EV/FCF ratio of -4.28.
- EV to Sales
- 2.89
- EV to EBITDA
- -6.79
- EV to Free Cash Flow
- -4.28
- EV to Operating Cash Flow
- -4.35
Balance Sheet
TriSalus Life Sciences has $41.06M in cash and marketable securities with $33.69M in debt, giving a net cash position of $7.37M billion.
- Cash & Marketable Securities
- $41.06M
- Total Debt
- $33.69M
- Net Cash
- $7.37M
- Net Cash Per Share
- $0.12
- Tangible Book Value Per Share
- $0.01
Margins
Gross margin is 86.46%, with operating margin of -62.95%, and net profit margin of -56.60%.
- Gross Margin
- 86.46%
- Operating Margin
- -62.95%
- Pretax Margin
- -56.57%
- Net Profit Margin
- -56.60%
- EBITDA Margin
- -42.62%
- EBIT Margin
- -43.77%
Analyst Forecast
The average price target for TriSalus Life Sciences is $6.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $6.67
- Price Target Upside
- 189.86% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- 15.38%
- EPS Growth Forecast
- 75.82%
Scores
- Smart Score
- 5
- AI Score
- 45
